Hyperion Therapeutics To Present At Jefferies 2014 Global Healthcare Conference

BRISBANE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) today announced that the company is scheduled to present at the Jefferies Global Healthcare Conference on Tuesday, June 3, 2014, at 1:30 p.m. ET.

Donald J. Santel, chief executive officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI ® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL ® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed in ex-U.S. geographies through business partners. Upon closing of the recently announced acquisition of Andromeda Biotech Ltd., the company will also own DiaPep277 ®, a first-in-class immune intervention therapy for new onset Type 1 diabetes. For more information, please visit www.hyperiontx.com.
CONTACT: Myesha Edwards         Corporate Communications and Investor Relations         (650) 745-7829

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX